» Articles » PMID: 15870132

Vascular Dysfunction and Metabolic Parameters in Polycystic Ovary Syndrome

Overview
Specialty Endocrinology
Date 2005 May 5
PMID 15870132
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Polycystic ovary syndrome (PCOS) is associated with insulin resistance (IR) and the metabolic syndrome; however, the cardiovascular (CV) manifestations of PCOS remain unclear.

Objective: The objective of this study was to examine the relationships between IR, metabolic parameters, androgens, and markers of early CV disease in PCOS.

Design: We conducted an observational study examining noninvasive markers of early CV disease in women with PCOS including structural [carotid intimal media thickness (IMT)] and functional measures (arterial function with pulse wave velocity and endothelial function with brachial arterial flow-mediated vasodilation). Metabolic parameters included insulin and glucose during an oral glucose tolerance test and lipid and androgen levels.

Setting: Participants were recruited from the general community.

Patients: Eighty overweight women with PCOS who were nonsmokers and not on oral contraceptives or other medications known to affect IR participated in the study.

Results: Stepwise regression analysis showed that after adjustment for age and body mass index, IMT was significantly correlated with blood pressure (BP) load (P = 0.03) and inversely with dehydroepiandrosterone sulfate (DHEAS) (P = 0.01). After correction for androgen status, IMT was correlated with fasting glucose and area under curve (AUC) insulin. Flow-mediated vasodilation was inversely related to lipids (P = 0.02), whereas pulse wave velocity was related to BP (P < 0.001), AUC insulin (P = 0.04), and AUC glucose (P = 0.035).

Conclusion: In overweight women with PCOS, insulin resistance and BP interacted negatively with arterial structural and functional measures. DHEAS correlated inversely with arterial structure, suggesting possible cardioprotective effects of endogenous DHEAS in women with PCOS. Additional research is needed to clarify these findings.

Citing Articles

Etanercept Ameliorates Vascular, Endocrine, and Ovarian Changes in a Rat Model of DHEA-Induced Polycystic Ovary Syndrome.

Utkan Korun Z, Gocmez S, Rencber S, Kavram Sarihan K, Eraldemir F, Sahin D Reprod Sci. 2023; 31(3):714-726.

PMID: 37932553 DOI: 10.1007/s43032-023-01392-9.


An update on polycystic ovary syndrome: A review of the current state of knowledge in diagnosis, genetic etiology, and emerging treatment options.

Islam H, Masud J, Islam Y, Haque F Womens Health (Lond). 2022; 18:17455057221117966.

PMID: 35972046 PMC: 9386861. DOI: 10.1177/17455057221117966.


Cardio-Metabolic Disease and Polycystic Ovarian Syndrome (PCOS): A Narrative Review.

Sangaraju S, Yepez D, Grandes X, Manjunatha R, Habib S Cureus. 2022; 14(5):e25076.

PMID: 35719759 PMC: 9203254. DOI: 10.7759/cureus.25076.


Turmeric extract alleviates endocrine-metabolic disturbances in letrozole-induced PCOS by increasing adiponectin circulation: A comparison with Metformin.

Shah M, Shrivastava V Metabol Open. 2022; 13:100160.

PMID: 35005596 PMC: 8717583. DOI: 10.1016/j.metop.2021.100160.


Group-based developmental BMI trajectories, polycystic ovary syndrome, and gestational diabetes: a community-based longitudinal study.

Sultana Kakoly N, Earnest A, Moran L, Teede H, Joham A BMC Med. 2017; 15(1):195.

PMID: 29110650 PMC: 5674239. DOI: 10.1186/s12916-017-0957-7.